Seagen Inc. (SGEN) and Astellas Pharma Inc. reported positive topline results from the Phase 3 EV-302 trial for PADCEV in combination with KEYTRUDA versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer. The company said the EV-302 study met dual primary endpoints of overall survival and progression-free survival, compared to chemotherapy.

Seagen Inc.（SGEN）和Astellas Pharma Inc.报告了PADCEV联合KEYTRUDA与化疗治疗先前未治疗的局部晚期或转移性尿路上皮癌患者的3期EV-302试验的阳性结果。该公司表示，与化疗相比，EV-302研究符合总生存期和无进展生存期的双重主要终点。

The company noted that EV-302 trial is intended to serve as the basis for global submissions and as the confirmatory trial for the U.S. accelerated approval of this combination. For More Such Health News, visit rttnews.com. For comments and feedback contact: editorial@rttnews.comBusiness News.

该公司指出，EV-302试验旨在作为全球提交的基础，并作为美国加速批准该组合的确认试验。有关更多此类健康新闻，请访问rttnews.com。获取评论和反馈联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision in August 2023

2023年8月FDA决定面临的生物技术股票

Biotech Stocks Facing FDA Decision In June 2023

2023年6月FDA决定面临的生物技术股票

Biotech Stocks Facing FDA Decision In April 2023

2023年4月面临FDA决定的生物技术股票